KRAS and cancer: These observations suggest that deltarasin elevates cellular ROS, which promotes autophagy (Zhang et al., 2016), and that deltarasin in combination with an autophagy inhibitor can be a plausible strategy for treating K-Ras–driven cancers (Leung et al., 2018).